iNtRON Biotechnology Temettü

Temettü kriter kontrolleri 1/6

iNtRON Biotechnology 1.7% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

1.7%

Temettü verimi

0.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	2.1%
Gelecekteki Temettü Verimi	1.7%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	₩100.000
Ödeme oranı	-54%

Son temettü güncellemeleri

Recent updates

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: A048530 'un temettü ödemelerinin istikrarlı olup olmadığını söylemek için henüz çok erken, zira şirket henüz temettü ödemeye başladı.

Büyüyen Temettü: A048530 'un temettü ödemelerinin artıp artmadığını söylemek için henüz çok erken, zira şirket henüz temettü ödemeye başladı.

Piyasaya Karşı Temettü Getirisi

iNtRON Biotechnology Piyasaya Karşı Temettü Getirisi

A048530 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (A048530)	1.7%
Pazarın Alt %25'i (KR)	1.2%
Pazarın En İyi %25'i (KR)	3.7%
Sektör Ortalaması (Biotechs)	0.5%
Analist tahmini (A048530) (3 yıla kadar)	1.7%

Önemli Temettü: A048530 'in temettüsü ( 1.7% ), KR piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.17% ) daha yüksektir.

Yüksek Temettü: A048530 'in temettüsü ( 1.7% ), KR piyasasındaki temettü ödeyenlerin en üst %25'ine ( 3.73% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: A048530 temettü ödüyor ancak şirket kâr etmiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: A048530 temettü ödüyor ancak şirketin serbest nakit akışı yok.

iNtRON Biotechnology Temettü

Temettü kriter kontrolleri 1/6

Anahtar bilgiler

Son temettü güncellemeleri

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Recent updates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Full year 2023 earnings released: ₩292 loss per share (vs ₩168 profit in FY 2022)

Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 30%

iNtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome

Full year 2022 earnings released: EPS: ₩168 (vs ₩288 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

iNtRON Biotechnology, Inc. Confirms the Efficacy of BAL200, A Novel Endolysin Biologic for Inhalational Anthrax

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Price target decreased to ₩16,400

iNtRON Developed Advanced Bacteriophage Engineering Platform Technology Based on Modified Random Mutagenesis

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Develops New CRISPR/Cas Technology Specific for Bacteriophage as PHAGERUS® Platform

iNtRON Biotechnology, Inc. Confirms Efficacy of Cdl200 Against CDI Clinical Isolates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology Completes GLP-TOX Studies of BAL200

Price target decreased to ₩16,400

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology, Inc. announced that it has received KRW 40 billion in funding

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc., Annual General Meeting, Mar 25, 2021

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

New 90-day high: ₩23,000

Investor sentiment improved over the past week

Market bids up stock over the past week

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

New 90-day high: ₩17,050

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

New 90-day low: ₩13,800

New 90-day high - ₩18,100

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin